Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Aarcoron May 06, 2021 1:01pm
112 Views
Post# 33141569

RE:RE:RE:RE:RE:RE:RE:RE:How Low Can It Go?

RE:RE:RE:RE:RE:RE:RE:RE:How Low Can It Go?I am just an anonymous shareholder with several hundred thousand shares of stock that are far under water.

I appreciate your historical review.  If true, I don't know who these shareholders are who have demanded no financings at 20 cents and created the "let's wait for someone to help us" business plan.  Whoemever they are, and I assume it is the BoD, are not good business people.  They seem to have no sense of urgency or clue that pharma is not there to maximize the value of BTI.  They seem to have no means of raising cash independently.  They are unable to generate any monetizable interest in the company.

Personally, I would be delighted to dilute 50% to get us through phase 2 on the lead program.  After that, xb3 would likely either be declared a dud or hold huge promise.  If the latter, phase 3 would find a way to get done.

I have paid my ticket to get to the dance, and I want to see this management group stop postponing the date.  At that point, xb3 will either rise or fall on its own merits and we will have all reached the point we have expected all along.  Until then, this management group is holding back xb3.  I would like to see every one of them replaced with business people who have a sense of urgency and can get this to the lab.  A decade of failure is more than enough patience.
<< Previous
Bullboard Posts
Next >>